This company is in an early growth phase with technology that has global implications along with an FDA approval ready in the pipeline.
All companies will suffer during this period, one would be foolish to expect otherwise.
I expect this company to make its mark in the medical industry when the world rebalances.
Ann: Quarterly Cash Flow and Summary of Activities, page-130
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IME (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
49.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $22.31M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 42.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 8300 | 1 |
View Market Depth
| Last trade - 16.12pm 01/07/2024 (20 minute delay) ? |
| IME (ASX) Chart |
Day chart unavailable